THE DEAL, AT A GLANCE
From the announcementReplimune
01Who is involvedBacked by VariousFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedReplimune raised $100M Growth RoundFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersReplimune is funding oncolytic virus immunotherapy development around RP1 and RP2, with RP1 + nivolumab showing 36% CR in anti-PD1 failed melanoma patients.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Replimune · Financing Record
Explore source-linked visual explanations for Replimune. Unsupported claims are withheld while source review continues.
Record 1666 · Recorded date: Needs review
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →